Compare EQX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQX | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | EQX | VERA |
|---|---|---|
| Price | $14.48 | $48.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $17.00 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 9.2M | 1.4M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $2,296,356,000.00 | N/A |
| Revenue This Year | $78.98 | N/A |
| Revenue Next Year | $29.11 | N/A |
| P/E Ratio | $127.31 | ★ N/A |
| Revenue Growth | ★ 85.65 | N/A |
| 52 Week Low | $5.04 | $18.53 |
| 52 Week High | $15.10 | $56.05 |
| Indicator | EQX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 58.17 |
| Support Level | $13.32 | $45.50 |
| Resistance Level | $14.67 | $56.05 |
| Average True Range (ATR) | 0.56 | 2.43 |
| MACD | -0.08 | -1.18 |
| Stochastic Oscillator | 65.24 | 31.28 |
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.